RESPONSE TO NEOADYAVANT CHEMOTHERAPY WITH PLATINUM-BASED DRUGS IN BREAST CANCER PATIENTS WITH BRCA1 DELETION IN TUMOR

Currently, the presence of the germinal mutation BRCA1 5382insC in breast cancer patients is one of the determining factors for prescribing platinum-based drugs. However, this type of mutation is found in no more than 10 % of patients, thus limiting the feasibility of administering platinum-based drugs. Various somatic changes in the BRCA1 gene in breast tumors, in particular the deletions of this gene, can play an important role in the tumor sensitivity to platinum drugs.

Case description. We present the case of a 42-year-old woman diagnosed with breast cancer. The deletion of the BRCA1 gene was detected in the tumor. The patient had a complete response to preoperative chemotherapy according to the CP regimen.

Conclusion. The frequency of the germline mutation of the BRCA1 gene does not exceed 10 %, and the deletion frequency of this gene can vary from 30 to 45 %, thus greatly increasing the feasibility of using platinum-based drugs in mutationnegative patients to achieve complete pathologic response and high survival rates.

1. Johnson N., Fletcher O., Palles C., Rudd M., Webb E., Sellick G., dos Santos Silva I., McCormack V., Gibson L., Fraser A., Leonard A., Gilham C., Tavtigian S.V., Ashworth A., Houlston R., Peto J. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 2007 May 1; 16(9): 1051–7. doi: 10.1093/hmg/ddm050.

2. Kadouri L., Hubert A., Rotenberg Y., Hamburger T., Sagi M., Nechushtan C., Abeliovich D., Peretz T. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007 Jul; 44(7): 467–71. doi: 10.1136/jmg.2006.048173.

3. Simard J., Tonin P., Durocher F., Morgan K., Rommens J., Gingras S., Samson C., Leblanc J.F., Bélanger C., Dion F. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 1994 Dec; 8(4): 392–8. doi: 10.1038/ng1294-392.

4. Palmero E.I., Alemar B., Schüler-Faccini L., Hainaut P., MoreiraFilho C.A., Ewald I.P., Santos P.K.D., Ribeiro P.L.I., Oliveira Netto C.B.D., Kelm F.L.C. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol. 2016 May 24; 39(2): 210–22. doi: 10.1590/1678-4685-GMB-2014-0363.

5. Byrski T., Huzarski T., Dent R., Gronwald J., Zuziak D., Cybulski C., Kladny J., Gorski B., Lubinski J., Narod S. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009 May; 115(2): 359–63. doi: 10.1007/s10549-008-0128-9

6. Byrski T., Huzarski T., Dent R., Marczyk E., Jasiowka M., Gronwald J., Jakubowicz J., Cybulski C., Wisniowski R., Godlewski D., Lubinski J., Narod S.A. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014 Sep; 147(2): 401–5. doi: 10.1007/s10549-014-3100-x.

7. Gafton I.G., Imyanitov E.N., Semiglasov V.V., Matsko D.E., Gafton G.I., Semiletova Yu.V., Ievleva A.G., Mikhnin A.E., Lemekhov V.G. BRCA1 gene expression in endocrine tumors of the gastrointestinal tract. Siberian Journal of Oncology. 2014; 16(4): 11–15. (in Russian)].

8. Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 2011 Aug 6; 9(1): 5. doi: 10.1186/18974287-9-5.

9. Tsyganov M., Ibragimova M., Deryusheva I., Slonimskaya E., Litviakov N. Expression of the BRCA1 gene in a breast tumor: Correlation with the effect of neoadjuvant chemotherapy. AIP Conference Proceedings. 2017; 1882(1): 1–5.

10. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic acids research. 2001; 29(9): e45e45.